Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide

Oncology

Volumn 77, Issue 2, 2008, Pages 134-139

  Kim, Seung Jin ^a   Taguchi, Tetsuya ^a   Shimazu, Kenzo ^a   Tanji, Yoshio ^a   Tamaki, Yasuhiro ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Predictor factor; Response

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN DERIVATIVE; GOSERELIN; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOLOGY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOLOGY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; PACLITAXEL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 67651007761     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000229753     Document Type: Article

References (23)

1. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006; 24: 1940-1949.
2. Buzdar AU: Preoperative chemotherapy treatment of breast cancer - a review. Cancer 2007; 110: 2394-2407.
3. Charfare H, Limongelli S, Purushotham AD: Neoadjuvant chemotherapy in breast cancer. Br J Cancer 2005; 92: 14-23.
4. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on loco-regional disease in women with operable breast cancer: findings from National Surgical Ad-juvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-2493.
5. Makris A, Powles TJ, Ashley SE, et al: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemo-endocrine therapy in primary breast cancer. Ann Oncol 1998; 9: 1179-1184.
6. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and ax-illary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin On-col 1999; 17: 460-469.
7. Rastogi P, Anderson SJ, Bear HD, et al: Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785.
8. Mazouni C, Kau SW, Frye D, et al: Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 2007; 18: 874-880.
9. Colleoni M, Viale G, Zahrieh D, et al: Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol 2008; 19: 465-472.
10. Goldstein NS, Decker D, Severson D, et al: Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 2007; 110: 1687-1696.
11. Iwao-Koizumi K, Matoba R, Ueno N, et al: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005; 23: 422-431.
12. Cuppone F, Bria E, Carlini P, et al: Taxanes as primary chemotherapy for early breast cancer. Cancer 2008; 113: 238-246.
13. Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005; 23: 5983-5992.
14. Padhani AR, Hayes C, Assersohn L, et al: Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging. Radiology 2006; 239: 361-374.
15. Segara D, Krop IE, Garber JE, et al: Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 2007; 96: 474-480.
16. Chen JH, Feig B, Agrawal G, et al: MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 2008; 112: 17-26.
17. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583. (Pubitemid 41511089)
18. Dhesy-Thind B, Pritchard KI, Messersmith H, et al: HER2/neu in systemic therapy for women with breast cancer: a systemic review. Breast Cancer Res Treat 2008; 109: 209-229.
19. Pritchard KI, Messersmith H, Elavathil L, et al: HER-2 and Topoisomerase II as predictors of response to chemotherapy. J Clin On-col 2008; 26: 736-744.
20. Smith IC, Heys SD, Hutckeon AW, et al: Neo-adjuvant chemotherapy in breast cancer: significantly enhanced response with docetax-el. J Clin Oncol 2002; 20: 1456-1466.
21. Blum JL, Jones SE, Buzdar AU, et al: Multi-center phase II study of capecitabine in pa-clitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-493.
22. Zelek L, Barthier S, Riofrio M, et al: Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001; 92: 2267-2272.
23. Seidman AD: Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology 2001; 15(suppl):11-14.